Goldman Sachs raised its rating on Zimmer Holdings ZMH from Sell to Neutral and increased its price target from $58 to $70.
Goldman Sachs noted, "Our investment thesis is based on the following factors: (1) improving outlook on US orthopaedic surgical volumes; (2) decelerating rates of pricing pressure; (3) capital allocation optionality with the potential for larger free cash flow returns to shareholders; and (4) shares appear fairly valued at current levels. Since being added to the Americas Sell List on August 9, 2011, ZMH shares are up 20.5% vs. the S&P 500 up 21.0%. On a trailing 12-month basis, ZMH is +33.0% vs. the S&P 500 +13.0%."
Zimmer Holdings closed at $65.50 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in